AU2020230963B2 - Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof - Google Patents

Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof

Info

Publication number
AU2020230963B2
AU2020230963B2 AU2020230963A AU2020230963A AU2020230963B2 AU 2020230963 B2 AU2020230963 B2 AU 2020230963B2 AU 2020230963 A AU2020230963 A AU 2020230963A AU 2020230963 A AU2020230963 A AU 2020230963A AU 2020230963 B2 AU2020230963 B2 AU 2020230963B2
Authority
AU
Australia
Prior art keywords
cyfra21
areg
flt3l
clec2c
erbb4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020230963A
Other languages
English (en)
Other versions
AU2020230963A1 (en
Inventor
Rocío ARROYO ARRANZ
Ana Carmen MARTÍN RODRÍGUEZ
Rosa PÉREZ PALACIOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Marker Discovery SL AMADIX
Original Assignee
Advanced Marker Discovery SL AMADIX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Marker Discovery SL AMADIX filed Critical Advanced Marker Discovery SL AMADIX
Publication of AU2020230963A1 publication Critical patent/AU2020230963A1/en
Application granted granted Critical
Publication of AU2020230963B2 publication Critical patent/AU2020230963B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2020230963A 2019-03-01 2020-02-28 Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof Active AU2020230963B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382157.6 2019-03-01
EP19382157 2019-03-01
EP19382156 2019-03-01
EP19382156.8 2019-03-01
PCT/EP2020/055277 WO2020178172A1 (en) 2019-03-01 2020-02-28 Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof

Publications (2)

Publication Number Publication Date
AU2020230963A1 AU2020230963A1 (en) 2021-09-30
AU2020230963B2 true AU2020230963B2 (en) 2026-03-12

Family

ID=69631636

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020230963A Active AU2020230963B2 (en) 2019-03-01 2020-02-28 Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof

Country Status (10)

Country Link
US (1) US20220276249A1 (https=)
EP (1) EP3931571B1 (https=)
JP (2) JP2022522803A (https=)
KR (1) KR102769007B1 (https=)
CN (1) CN113785199B (https=)
AU (1) AU2020230963B2 (https=)
CA (1) CA3131729A1 (https=)
ES (1) ES2952139T3 (https=)
MX (1) MX2021010451A (https=)
WO (1) WO2020178172A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
WO2021185982A1 (en) * 2020-03-19 2021-09-23 Advanced Marker Discovery S.l. Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
KR102900859B1 (ko) * 2021-12-31 2025-12-17 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066915A1 (en) * 2004-12-23 2006-06-29 Roche Diagnostics Gmbh Use of cyfra 21-1 as a marker for colorectal cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101896817A (zh) * 2007-12-10 2010-11-24 霍夫曼-拉罗奇有限公司 用于结直肠癌的标记物组
CN103140760B (zh) * 2010-07-14 2016-01-27 联邦科学与工业研究组织 结肠直肠癌的诊断
US20140220006A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Lung cancer biomarkers
US20160291025A1 (en) * 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
JP6339399B2 (ja) * 2014-03-28 2018-06-06 学校法人北里研究所 卵巣明細胞腺癌細胞の検出方法、卵巣明細胞腺癌診断薬、卵巣明細胞腺癌診断用プライマー、卵巣明細胞腺癌診断用キット、及び卵巣明細胞腺癌診断用プローブ
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
JP2018136122A (ja) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
US20180160885A1 (en) * 2016-12-13 2018-06-14 Prosper Abitbol Endoscopy based medical devices, methods, and innovations
KR102018205B1 (ko) * 2017-07-24 2019-09-05 (주) 바이오인프라생명과학 대장암 진단용 조성물 및 상기 조성물을 이용한 대장암 진단 방법
US10968583B2 (en) * 2017-07-26 2021-04-06 David E. Lambert Reflective road marker
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
WO2021185982A1 (en) * 2020-03-19 2021-09-23 Advanced Marker Discovery S.l. Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066915A1 (en) * 2004-12-23 2006-06-29 Roche Diagnostics Gmbh Use of cyfra 21-1 as a marker for colorectal cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chen, H. et al. (2015) 'Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer,' Clinical Cancer Research, 21(14):3318-3326, doi:10.1158/1078-0432.ccr-14-3051. *
Chen, H. et al. (2017), Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer, Clinical Epidemiology, 9 517-526, with suppl. materials. *

Also Published As

Publication number Publication date
US20220276249A1 (en) 2022-09-01
AU2020230963A1 (en) 2021-09-30
CN113785199A (zh) 2021-12-10
EP3931571B1 (en) 2023-06-07
JP2022522803A (ja) 2022-04-20
BR112021017248A2 (pt) 2021-11-09
EP3931571C0 (en) 2023-06-07
KR102769007B1 (ko) 2025-02-14
ES2952139T3 (es) 2023-10-27
CA3131729A1 (en) 2020-09-10
JP2025038186A (ja) 2025-03-18
WO2020178172A1 (en) 2020-09-10
EP3931571A1 (en) 2022-01-05
KR20210134946A (ko) 2021-11-11
MX2021010451A (es) 2021-12-10
CN113785199B (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
AU2020230963B2 (en) Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof
US10408839B2 (en) Biomarker panel for diagnosing cancer
US11193935B2 (en) Compositions, methods and kits for diagnosis of lung cancer
KR102061441B1 (ko) 폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트
JP2017133831A (ja) 大腸がんの転移検出方法
CN118465282A (zh) 预测结直肠癌肝转移的生物标志物组合、试剂盒、系统及其应用
JP7727970B2 (ja) 結腸直腸癌および／またはその前癌段階の診断またはスクリーニングのための非侵襲的方法
Du et al. Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA
TW201439122A (zh) 膀胱及腎臟癌之尿液生物標記及其應用
US20230204584A1 (en) Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof
CN120210363A (zh) 用于诊断晚期鼻咽癌的生物标志物及其应用
EP4357782A1 (en) Protein biomarker panel for the diagnosis of colorectal cancer
US20140287939A1 (en) Biomarker(s) for early detection / diagnosis/ prognosis of gastric cancer
RU2830580C2 (ru) Белковая сигнатура для диагностики колоректального рака или его предраковой стадии
WO2024004523A1 (ja) 大腸がんバイオマーカーおよびその用途
BR112021017248B1 (pt) Método in vitro para o diagnóstico de câncer colorretal e/ou um seu estágio pré- canceroso, usos in vitro da combinação de [flt3l e cyfra21-1] e da combinação de da combinação de [flt3l e cyfra21-1 e areg], ou [flt3l e cyfra21-1 e areg e erbb4], ou {flt3l e cyfra21-1 e areg e clec2c] em uma amostra biológica obtida do paciente,e uso de um kit de partes
CN117169504B (zh) 用于胃癌相关参数检测的生物标志物及相关预测系统及应用
Al-Athwary et al. A tumor-associated autoantibody panel for early detection of breast cancer in Sana’a, Yemen
WO2026068798A1 (en) Sox9 for assessing colorectal cancer (crc) or a precancerous condition thereof
CN119804865A (zh) 细胞外囊泡蛋白质作为诊断腹主动脉瘤的生物标志物及应用
CN121713068A (zh) 癌症的检测辅助方法以及检测试剂盒
CN118584108A (zh) 一种体外检测胃癌的系统
US20160060708A1 (en) Method for detecting the risk of early gastric cancer